Want to see XLO full AI Analyst Report?
XLO Stock Chart & Stats
$8.65
$0.44(5.09%)
At close: 4:00 PM EDT
$8.65
$0.44(5.09%)
Day’s Range― - ―
52-Week Range$6.46 - $12.74
Previous Close$9.03
Volume37.59K
Average Volume (3M)48.17K
Market Cap
$59.90M
Enterprise Value-$6.21
Total Cash (Recent Filing)$150.33M
Total Debt (Recent Filing)$6.64M
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Aug 12, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.50
Shares Outstanding6,575,139
10 Day Avg. Volume75,329
30 Day Avg. Volume48,168
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)21.23
Price to Sales (P/S)17.11
P/FCF Ratio-135.93
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.02
Revenue Forecast (FY)$36.01M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentManagement aims to partner with other companies to advance the clinical development of vilastobart, showing a proactive approach in expanding potential market reach.
Financial StabilityThe company ended the quarter with $121.6M in cash and cash equivalents, which should sustain operations into 3Q26.
InnovationXilio is on track with strategic nominations for developing targeted therapies, reflecting a clear pipeline and focus on innovation.
Bears Say
Financial PerformanceXilio reported a net loss of $16.3 million, indicating financial challenges that need to be addressed.
Strategic PartnershipsFinding the right partner quickly is critical for both the asset and the company.
Xilio Therapeutics News
XLO FAQ
What was Xilio Therapeutics’s price range in the past 12 months?
Xilio Therapeutics lowest stock price was $6.46 and its highest was $12.74 in the past 12 months.
What is Xilio Therapeutics’s market cap?
Xilio Therapeutics’s market cap is $59.90M.
When is Xilio Therapeutics’s upcoming earnings report date?
Xilio Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 9 days.
How were Xilio Therapeutics’s earnings last quarter?
Xilio Therapeutics released its earnings results on May 12, 2026. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.66 by $0.08.
Is Xilio Therapeutics overvalued?
According to Wall Street analysts Xilio Therapeutics’s price is currently Overvalued.
Does Xilio Therapeutics pay dividends?
Xilio Therapeutics does not currently pay dividends.
What is Xilio Therapeutics’s EPS estimate?
Xilio Therapeutics’s EPS estimate is -0.59.
How many shares outstanding does Xilio Therapeutics have?
Xilio Therapeutics has 6,575,139 shares outstanding.
What happened to Xilio Therapeutics’s price movement after its last earnings report?
Xilio Therapeutics reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.66. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Xilio Therapeutics?
Currently, no hedge funds are holding shares in XLO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xilio Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
57.63%
Trailing 12-Months
Company Description
Xilio Therapeutics
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
Technical Analysis
Forte Biosciences
―
X4 Pharmaceuticals
―
Lantern Pharma
―
Connect Biopharma Holdings
―
OKYO Pharma Limited Sponsored ADR
―